De-escalating low-dose rituximab up to every 24-month infusions and the risk of disease activity in people with relapsing multiple sclerosis who were stable the first year on therapy

Annette Langer-Gould; Jessica B Smith; A. Scott Nielsen; Brandon Beaber; Sonu M. Brara; Samira Amirova; Elaine Su; Bonnie H Li; Neda Zarghami Esfahani; Fernando Araripe Gonçalves Torres; Stanley Xu

doi:10.1177/13524585261430130

March 19, 2026Multiple Sclerosis Journal

De-escalating low-dose rituximab up to every 24-month infusions and the risk of disease activity in people with relapsing multiple sclerosis who were stable the first year on therapy

View Full Paper

Ask AI

Bookmark

Share

Key Points

To determine the risk of disease activity when extending low-dose rituximab infusions to every 24 months in stable relapsing multiple sclerosis patients.
Analyzed a large population-based cohort of individuals with relapsing multiple sclerosis.
Compared disease activity in patients receiving infusions every 24 months to those receiving them every 6-12 months.
Evaluated clinical and radiological stability after one year on therapy.
No increase in disease activity was observed in patients extending infusions to every 24 months.
Patients were clinically and radiologically stable during the first year on therapy.
De-escalation strategy appears to maintain disease control without added risk.

Implication

Research shows extending low-dose rituximab infusions in relapsing multiple sclerosis does not increase disease activity, suggesting a safe de-escalation approach.

Abstract

Extending low-dose rituximab after at least 1 year of clinical and radiological stability up to q24mo was not associated with an increased risk of disease activity compared to continuing q6-12mo intervals in this large, population-based cohort.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Langer-Gould et al. (2026) studied this question.

synapsesocial.com/papers/69be38126e48c4981c67840a https://doi.org/10.1177/13524585261430130

View Full Paper

Ask AI

Bookmark

Share

De-escalating low-dose rituximab up to every 24-month infusions and the risk of disease activity in people with relapsing multiple sclerosis who were stable the first year on therapy

Key Points

Implication

Abstract

Discussion

Cite This Study

De-escalating low-dose rituximab up to every 24-month infusions and the risk of disease activity in people with relapsing multiple sclerosis who were stable the first year on therapy

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading